As shown in Figure 5C, the tumor growth of MDA-MB-468 co-grafts with 3T3HAS3 CD44 KO T1 and T2 was slightly reduced when compared with MDA-MB-468 + 3T3HAS3 co-grafts (at last data point analyzed, the average tumor sizes of T1 and T2 co-grafts were 82.2% and 76.4% of MDA-MB-468 + 3T3HAS3 co-grafts, respectively). This evidence concerns the gene CD44 and neoplasm.